Enhanced in vivo therapeutic response to interferon in mice with an in vitro interferon-resistant B-cell lymphoma.
A stable subline of 38C13 B-cell lymphoma (SIR-1) resistant to the antiproliferative effects of alpha-interferon (IFN) was isolated. In addition to defects in antiproliferative effects of IFN, SIR-1 is defective in IFN-mediated antiviral activity against both encephalomyocarditis virus and vesicularstomatitis virus. It is also defective in the induction of 2'-5'-oligoadenylate synthetase mRNA and enzyme activity, enhancement of H-2 antigen expression, and transient induction and subsequent repression of c-myc by IFN. SIR-1, although completely resistant to IFN in vitro, is more sensitive to IFN than the parental cell line in vivo. IFN treatment at 10(4) units, three times weekly, resulted in a 28% increase in mean survival time and a 1.4% long term survival rate in the IFN-sensitive 38C13 cell line but resulted in a 275% increase in mean survival rate and a 27% long term survival rate in the interferon-resistant SIR-1 mutant. Statistical analysis of 38C13 and SIR-1 with and without IFN treatment demonstrate that: a) the SIR-1 mutant remains sensitive to the cytotoxic effects of IFN in vivo (P less than 0.0001); and b) the mean survival and long term survival of animals with the SIR-1 mutant is significantly greater than for animals with the IFN-sensitive 38C13 cell line (P less than 0.0001). Two additional independently isolated IFN-resistant cell lines (SIR-111 and SIR-E102) also demonstrate significantly enhanced in vivo response to IFN compared to the interferon-sensitive parental (38C13) cells. These results indicate that, for this cell line, the antitumor effects of IFN are mediated by activation of host defenses and that resistance to the in vitro cytotoxic effects of IFN results in a tumor phenotype that is more readily recognized by host defenses and eliminated.
Reid
T R
TR
Department of Medicine, Stanford University School of Medicine, California 94305.
Race
E R
ER
Wolff
B H
BH
Friedman
R M
RM
Merigan
T C
TC
Basham
T Y
TY
D015088:2',5'-Oligoadenylate Synthetase / Q000032:analysis; D000818:Animals; D001402:B-Lymphocytes; D004351:Drug Resistance; D006183:H-2 Antigens / Q000032:analysis; D007370:Interferon Type I / Q000494:pharmacology / Q000627:therapeutic use*; D008223:Lymphoma / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D051379:Mice; D008809:Mice, Inbred C3H; D011519:Proto-Oncogenes; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014780:Viruses / Q000187:drug effects
D006183:H-2 Antigens; D007370:Interferon Type I; D015088:2',5'-Oligoadenylate Synthetase